EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 123.38

Change

+0.96 (+0.78)%

Market Cap

USD 0.70B

Volume

9.32K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-25 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.13 (+0.26%)

USD 509.68B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.03 (+0.18%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.08 (+0.29%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.08 (+0.29%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.02 (+0.08%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+0.60 (+0.41%)

USD 100.74B
JARI:XETRA Amundi Index Solutions - Amund..

-0.02 (-0.03%)

USD 100.71B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.12 (+0.24%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-0.28 (-0.05%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.12 (+0.55%)

USD 79.79B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.86% 88% B+ 86% B+
Dividend Return 0.25% 12% F 6% D-
Total Return 17.11% 88% B+ 85% B
Trailing 12 Months  
Capital Gain 18.98% 72% C 72% C
Dividend Return 0.50% 14% F 8% B-
Total Return 19.48% 73% C 72% C
Trailing 5 Years  
Capital Gain 53.23% 72% C 72% C
Dividend Return 6.08% 63% D 36% F
Total Return 59.30% 75% C 73% C
Average Annual (5 Year Horizon)  
Capital Gain 6.10% 56% F 56% F
Dividend Return 6.99% 61% D- 58% F
Total Return N/A 34% F 35% F
Risk Return Profile  
Volatility (Standard Deviation) 8.18% 68% D+ 75% C
Risk Adjusted Return 85.45% 93% A 93% A
Market Capitalization 0.70B 73% C 64% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.